Status:
TERMINATED
Nausea and Vomiting In Patients Receiving Consecutive Days of Cisplatin
Lead Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Metastatic Melanoma
Nausea
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to observe the incidence of nausea with systemic chemotherapy that includes consecutive days (more than one day)of cisplatin medication.
Detailed Description
Questionnaires are completed on week of chemotherapy treatment referred to as Dartmouth regimen.
Eligibility Criteria
Inclusion
- confirmed diagnosis metastatic melanoma
- 18 years and older
- undergoing chemotherapy with Dartmouth regimen
- medically stable to receive chemotherapy per physical and clinical laboratory tests
Exclusion
- No medical conditions that interfere with assessment of nausea and vomiting during chemotherapy
- No cognitive disorder that impairs symptom assessment
- No other investigational agent
- Inability to swallow medications for nausea and vomiting
- No gastric outlet obstruction
Key Trial Info
Start Date :
May 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT00716560
Start Date
May 1 2005
End Date
March 1 2009
Last Update
May 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States, 19107